Currus Biologics

Melbourne, Australia · Founded 2020 · Privately Held (backing)

Developer of CAR-T cell therapies designed to treat solid cancers. Currus Biologics is based in Melbourne, Australia and was founded in 2020. Its last reported valuation was $21.6 million in Oct 2025. It has raised $19.3 million.

Last reported valuation
$21.6M
Oct 2026
Priced at
—
Total raised
$19.3M
Last round
—
No prints on record

No secondary trades in Currus Biologics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Currus Biologics with a free account
  • ·Watch Currus Biologics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where Currus Biologics prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Currus Biologics stock.